Solid Reports Positive Data for SGT-003 Gene Therapy in Phase 1/2 Trial of Duchenne

After 90 days of treatment, investigators observed positive findings on microdystrophin expression, as well as reductions in markers of muscle injury and stress, and muscle breakdown and dystrophic regeneration.:

Source: Neurology Read More